丹诺医药（苏州）有限公司

About Tennor

Company Overview

TenNor Therapeutics is a clinical-stage company with a sharp focus on research and development of new drugs to address unmet medical needs in infectious disease area.>>more

News Center

2020.03.20

Investigators from Mayo Clinic Publish Results of TNP-2092 against Periprosthetic Joint Infection-Associated Staphylococci

Please read the article through this link: https://www.sciencedirect.com/science/article/abs/pii/S0732889319307229
2020.01.30

BioWorld Reports Recent Progress of TenNor Therapeutics

Please read the details through this link: https://www.bioworld.com/articles/432589-tennors-prosthetic-joint-infections-therapy-tnp-2092-set-to-start-phase-iii-soon?v=preview
2020.01.20

TenNor Therapeutics Received FDA Orphan Drug Designation

SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.

About Tennor

Company Overview

News Center

Investigators from Mayo Clinic Publish Results of TNP-2092 against Periprosthetic Joint Infection-Associated Staphylococci

BioWorld Reports Recent Progress of TenNor Therapeutics

TenNor Therapeutics Received FDA Orphan Drug Designation